journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Technology & Therapeutics

journal
https://www.readbyqxmd.com/read/28605286/the-durability-of-basal-insulin-affects-day-to-day-glycemic-variability-assessed-by-continuous-glucose-monitoring-in-type-2-diabetes-patients-a-randomized-crossover-trial
#1
Hiroyuki Iuchi, Masaya Sakamoto, Daisuke Matsutani, Hirofumi Suzuki, Ryuzo Horiuchi, Kazunori Utsunomiya
BACKGROUND: Not only within-day glycemic variability but also day-to-day glycemic variability is a risk factor for diabetic patients. However, the ways of controlling day-to-day glycemic variability are unclear. We hypothesized that the durability of basal insulin plays an important role in controlling day-to-day glycemic variability in type 2 diabetes patients, and we therefore aimed to evaluate whether glargine U300, which exhibits prolonged absorption compared with glargine U100 but the same composition as glargine U100, would lead to improved day-to-day glycemic variability...
June 12, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28594575/bolus-calculator-reduces-hypoglycemia-in-the-short-term-and-fear-of-hypoglycemia-in-the-long-term-in-subjects-with-type-1-diabetes-cbmdi-study
#2
María Del Rosario Vallejo Mora, Monica Carreira, María Teresa Anarte, Francisca Linares, Gabriel Olveira, Stella González Romero
BACKGROUND: In a previous study we demonstrated improvement in metabolic control and reduction in hypoglycemia in people with type 1 diabetes on multiple daily injections, after having used a bolus calculator for 4 months. OBJECTIVE: To demonstrate whether (1) extending its use (2) or introducing it in the control group, previously subjected to treatment intensification, could further improve metabolic control and related psychological issues. METHODS: After the previous clinical trial, in which the subjects were randomized either to treatment with the calculator or to control group for 4 months, both groups used the calculator during an additional 4-month period...
June 8, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28594566/severe-hypoglycemia-before-landing-in-a-patient-with-type-1-diabetes-using-sensor-augmented-pump-therapy
#3
Clara Viñals, Adriana Pané, Carmen Quirós, Marga Giménez, Ignacio Conget
No abstract text is available yet for this article.
June 8, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28581821/randomized-controlled-trial-of-technology-assisted-case-management-in-low-income-adults-with-type-2-diabetes
#4
Leonard E Egede, Joni S Williams, Delia C Voronca, Rebecca G Knapp, Jyotika K Fernandes
OBJECTIVE: To assess the efficacy of technology-assisted case management (TACM) with medication titration by nurses using guideline-based algorithms, under physician supervision in improving glycemic control in low-income rural adults with poorly controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: Adults (aged ≥18 years) from the southeastern United States with hemoglobin A1c [HbA1c] ≥8% were randomized to TACM or usual care. Evidence-based guidelines were used to develop medication titration algorithms in conjunction with clinic physicians...
June 5, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28581818/effect-of-linagliptin-versus-metformin-on-glycemic-variability-in-patients-with-impaired-glucose-tolerance
#5
Tonatiuh González-Heredia, Diana M Hernández-Corona, Manuel González-Ortiz, Esperanza Martínez-Abundis
BACKGROUND: Impaired glucose tolerance (IGT) and glycemic variability may be associated with increased risk of micro- and macrovascular complications. The aim of this study was to assess the effect of linagliptin versus metformin on glycemic variability in patients with IGT. MATERIAL AND METHODS: A randomized, double-blind clinical trial with parallel groups was carried out in 16 adult patients with IGT, overweight or obesity. All patients signed an informed consent...
June 5, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28556672/faster-use-and-fewer-failures-with-needle-free-nasal-glucagon-versus-injectable-glucagon-in-severe-hypoglycemia-rescue-a-simulation-study
#6
Jean-François Yale, Hélène Dulude, Marc Egeth, Claude A Piché, Martin Lafontaine, Dolorès Carballo, Rebecca Margolies, Emily Dissinger, Adam R Shames, Nicole Kaplowitz, Michelle Xiaotian Zhang, Shuyu Zhang, Cristina B Guzman
BACKGROUND: During severe hypoglycemic episodes, people with diabetes depend on others to help with treatment. We compared needle-free nasal glucagon and commercially available injectable glucagon for ease of use by caregivers of people with diabetes and by others in treating simulated episodes of severe hypoglycemia. METHODS: Sixteen instructed caregivers and 15 noninstructed acquaintances administered nasal and injectable glucagon to manikins, simulating unconscious people with diabetes during severe hypoglycemia episodes...
May 30, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28537437/-it-is-definitely-a-game-changer-a-qualitative-study-of-experiences-with-in-home-overnight-closed-loop-technology-among-adults-with-type-1-diabetes
#7
Christel Hendrieckx, Lucinda A Poole, Amin Sharifi, Dilshani Jayawardene, Margaret M Loh, Jodie C Horsburgh, Leon A Bach, Peter G Colman, Kavita Kumareswaran, Alicia J Jenkins, Richard J MacIsaac, Glenn M Ward, Benyamin Grosman, Anirban Roy, David N O'Neal, Jane Speight
BACKGROUND: This qualitative study explored trial participants' experiences of four nights of in-home closed loop. METHODS: Sixteen adults with type 1 diabetes, who completed a randomized crossover trial, were interviewed after four consecutive nights of closed-loop. Interviews were audio recorded, transcribed, and analyzed with a coding framework developed to identify the main themes. RESULTS: Participants had a mean age of 42 ± 10 years, nine were women; mean diabetes duration was 27 ± 7 years, and all were using insulin pumps...
May 24, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28537427/overnight-counter-regulatory-hormone-levels-and-next-day-glycemia-in-adults-with-type-1-diabetes-during-closed-loop-insulin-delivery-versus-sensor-augmented-pump-with-low-glucose-suspend
#8
Anneke Graf, Glenn M Ward, Sara Vogrin, Vijaya Sundararajan, Amin Sharifi, Martin I De Bock, Dilshani Jayawardene, Margaret M Loh, Jodie C Horsburgh, Carolyn L Berthold, Nirubasini Paramalingam, Leon A Bach, Peter G Colman, Elizabeth A Davis, Benyamin Grosman, Alicia J Jenkins, Kavita Kumareswaran, Natalie Kurtz, Andrew Kyoong, Richard J MacIsaac, Anirban Roy, Timothy W Jones, David N O'Neal
No abstract text is available yet for this article.
May 24, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28530490/role-of-continuous-glucose-monitoring-in-clinical-trials-recommendations-on-reporting
#9
Oliver Schnell, Katharine Barnard, Richard Bergenstal, Emanuele Bosi, Satish Garg, Bruno Guerci, Thomas Haak, Irl B Hirsch, Linong Ji, Shashank R Joshi, Maarten Kamp, Lori Laffel, Mathieu Chantal, William H Polonsky, Frank Snoek, Philip Home
Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability...
May 22, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28463010/behavioral-patterns-and-associations-with-glucose-control-during-12-week-randomized-free-living-clinical-trial-of-day-and-night-hybrid-closed-loop-insulin-delivery-in-adults-with-type-1-diabetes
#10
Ali Emami, Malgorzata E Willinska, Hood Thabit, Lalantha Leelarathna, Sara Hartnell, Sibylle Dellweg, Carsten Benesch, Julia K Mader, Manuel Holzer, Harald Kojzar, Thomas R Pieber, Sabine Arnolds, Mark L Evans, Roman Hovorka
OBJECTIVES: We evaluated patterns of meal intake, insulin bolus delivery, and fingerstick glucose measurements during hybrid closed-loop and sensor-augmented pump (SAP) therapy, including associations with glucose control. METHODS: Data were retrospectively analyzed from pump-treated adults with type 1 diabetes who underwent, in random order, 12 weeks free-living closed-loop (n = 32) and 12 weeks SAP (n = 33) periods. We quantified daily patterns of main meals, snacks, prandial insulin boluses, correction boluses, and fingerstick glucose measurements by analyzing data recorded on the study glucometer and on study insulin pump...
May 2, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28613950/correction-to-diabetes-technol-ther-2017-19-5-299-304
#11
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28613949/importance-of-artificial-pancreas-standard-nomenclature
#12
Ananda Basu
No abstract text is available yet for this article.
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28613948/handling-exercise-during-closed-loop-control
#13
Marc D Breton
No abstract text is available yet for this article.
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28613947/the-effects-of-basal-insulin-suspension-at-the-start-of-exercise-on-blood-glucose-levels-during-continuous-versus-circuit-based-exercise-in-individuals-with-type-1-diabetes-on-continuous-subcutaneous-insulin-infusion
#14
Dessi Zaharieva, Loren Yavelberg, Veronica Jamnik, Ali Cinar, Kamuran Turksoy, Michael C Riddell
BACKGROUND: Exercise causes glycemic disturbances in individuals with type 1 diabetes (T1D). Continuous moderate-intensity aerobic exercise (CON) generally lowers blood glucose (BG) levels and often leads to hypoglycemia. In comparison, circuit-based exercise (CIRC) may attenuate the drop in BG. The goal of this study is to contrast the effects of basal insulin suspension at the onset of two different forms of exercise (CON vs. CIRC). METHODS: Twelve individuals (six men and six women) with T1D on insulin pump therapy were recruited for the study...
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28613946/automated-insulin-delivery-system-nomenclature
#15
Ohad Cohen, Robert A Vigersky, Scott W Lee, Toni L Cordero, Francine R Kaufman
No abstract text is available yet for this article.
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28585879/continuous-glucose-monitoring-a-review-of-recent-studies-demonstrating-improved-glycemic-outcomes
#16
David Rodbard
Continuous Glucose Monitoring (CGM) has been demonstrated to be clinically valuable, reducing risks of hypoglycemia and hyperglycemia, glycemic variability (GV), and improving patient quality of life for a wide range of patient populations and clinical indications. Use of CGM can help reduce HbA1c and mean glucose. One CGM device, with accuracy (%MARD) of approximately 10%, has recently been approved for self-adjustment of insulin dosages (nonadjuvant use) and approved for reimbursement for therapeutic use in the United States...
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28585878/practical-considerations-on-the-use-of-continuous-glucose-monitoring-in-pediatrics-and-older-adults-and-nonadjunctive-use
#17
Gregory P Forlenza, Nicholas B Argento, Lori M Laffel
Clinical use of continuous glucose monitoring (CGM) devices has grown over the past 15 years from a niche concept to becoming standard of care for patients with type 1 diabetes (T1D). With the December 2016 Food and Drug Administration approval for diabetes treatment decisions directly from CGM values (nonadjunctive use) without finger-stick confirmation, the uptake and scope of CGM use will likely further expand. With this expansion, it is important to consider the role and impact of CGM technology in specific settings and high-risk populations, such as the young and the elderly...
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28585877/future-of-automated-insulin-delivery-systems
#18
Jessica R Castle, J Hans DeVries, Boris Kovatchev
Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level...
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28585876/cgm-pregnancy-and-remote-monitoring
#19
Sarit Polsky, Rachel Garcetti
The glycemic goals of pregnancy are very narrow to reduce excess risks for numerous maternal and fetal complications. Continuous glucose monitors (CGMs) may help women achieve glucose goals and reduce hypoglycemia. CGM use has been found to be safe and effective in pregnancies associated with diabetes. CGM use can accurately identify glycemic patterns among women with and without diabetes in pregnancy. The data on the effects of CGM use on maternal and fetal outcomes are conflicting. Using CGMs in conjunction with continuous subcutaneous insulin infusion therapy in pregnancies complicated by diabetes may improve outcomes...
June 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28585875/continuous-glucose-monitoring-with-multiple-daily-insulin-treatment-outcome-studies
#20
Janet B McGill, Andrew Ahmann
Continuous glucose monitoring (CGM) is developing into an increasingly useful tool for glucose monitoring and therapeutic guidance in the treatment of diabetes. Multiple daily doses of insulin (MDI) is the most common method for intensive insulin treatment of type 1 diabetes and is also becoming more common in the treatment of type 2 diabetes as an increasing population with type 2 diabetes experiences progressive beta cell loss. The clinical evidence demonstrating the benefit of CGM in the outcomes of patients treated with MDI is becoming clearer, particularly with the recent completion of several randomized clinical trials addressing both type 1 and 2 diabetes...
June 2017: Diabetes Technology & Therapeutics
journal
journal
34712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"